Literature DB >> 34176619

Comparison of SYNTAX score strata effects of percutaneous and surgical revascularization trials: A meta-analysis.

Mario Gaudino1, Irbaz Hameed2, Antonino Di Franco3, Ajita Naik3, Michelle Demetres4, Giuseppe Biondi-Zoccai5, Sripal Bangalore6.   

Abstract

OBJECTIVES: The evidence supporting the use of the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) score for risk stratification is controversial. We performed a systematic review and meta-analysis of all the randomized controlled trials comparing percutaneous coronary intervention versus coronary artery bypass grafting that reported their outcomes stratified by SYNTAX score, focusing on between-strata comparisons.
METHODS: A systematic review of MEDLINE, EMBASE, Cochrane Library databases was performed. Incidence rate ratios were pooled with a random effect model. Between-group statistical heterogeneity according to accepted SYNTAX score tertiles was computed in the main analysis. Ratios of incidence rate ratios were computed to appraise between-strata effect, as sensitivity analysis. Primary and secondary outcomes were major adverse cardiac and cerebrovascular events and all-cause mortality, respectively. Separate sub-analyses were performed for left main and multivessel disease.
RESULTS: From 425 citations, 6 trials were eventually included (8269 patients [4134 percutaneous coronary interventions, 4135 coronary artery bypass graftings]; mean follow-up: 6.2 years [range: 3.8-10]). Overall, percutaneous coronary intervention was associated with a significant increase in major adverse cardiac and cerebrovascular events (incidence rate ratio, 1.39, 95% confidence interval, 1.27-1.51) and nonsignificant increase in all-cause mortality (incidence rate ratio, 1.17, 95% confidence interval, 0.98-1.40). There was no significant statistical heterogeneity of treatment effect by SYNTAX score for major adverse cardiac and cerebrovascular events or mortality (P = .40 and P = .34, respectively). Results were consistent also for patients with left main and multivessel disease (major adverse cardiac and cerebrovascular events: P = .85 in left main, P = .78 in multivessel disease 0.78; mortality: P = .12 in left main; P = .34 in multivessel disease). Results of analysis based on ratios of incidence rate ratios were consistent with the main analysis.
CONCLUSIONS: No significant association was found between SYNTAX score and the comparative effectiveness of percutaneous coronary intervention and coronary artery bypass grafting. These findings have implications for clinical practice, future guidelines, and the design of percutaneous coronary intervention versus coronary artery bypass grafting trials.
Copyright © 2021 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CABG; PCI; SYNTAX

Year:  2021        PMID: 34176619      PMCID: PMC8805094          DOI: 10.1016/j.jtcvs.2021.05.036

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  25 in total

Review 1.  The Choice of Conduits in Coronary Artery Bypass Surgery.

Authors:  Mario Gaudino; David Taggart; Hisayoshi Suma; John D Puskas; Filippo Crea; Massimo Massetti
Journal:  J Am Coll Cardiol       Date:  2015-10-13       Impact factor: 24.094

2.  Prognostic value of the Syntax score in patients undergoing coronary artery bypass grafting for three-vessel coronary artery disease.

Authors:  Gilles Lemesle; Laurent Bonello; Axel de Labriolle; Daniel H Steinberg; Probal Roy; Tina L Pinto Slottow; Rebecca Torguson; Kimberly Kaneshige; Zhenyi Xue; William O Suddath; Lowell F Satler; Kenneth M Kent; Joseph Lindsay; Augusto D Pichard; Ron Waksman
Journal:  Catheter Cardiovasc Interv       Date:  2009-04-01       Impact factor: 2.692

3.  Predicting major adverse cardiac events after percutaneous coronary intervention: the Texas Heart Institute risk score.

Authors:  Pankaj Madan; MacArthur A Elayda; Vei-Vei Lee; James M Wilson
Journal:  Am Heart J       Date:  2008-04-03       Impact factor: 4.749

4.  Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial.

Authors:  Timo Mäkikallio; Niels R Holm; Mitchell Lindsay; Mark S Spence; Andrejs Erglis; Ian B A Menown; Thor Trovik; Markku Eskola; Hannu Romppanen; Thomas Kellerth; Jan Ravkilde; Lisette O Jensen; Gintaras Kalinauskas; Rikard B A Linder; Markku Pentikainen; Anders Hervold; Adrian Banning; Azfar Zaman; Jamen Cotton; Erlend Eriksen; Sulev Margus; Henrik T Sørensen; Per H Nielsen; Matti Niemelä; Kari Kervinen; Jens F Lassen; Michael Maeng; Keith Oldroyd; Geoff Berg; Simon J Walsh; Colm G Hanratty; Indulis Kumsars; Peteris Stradins; Terje K Steigen; Ole Fröbert; Alastair N J Graham; Petter C Endresen; Matthias Corbascio; Olli Kajander; Uday Trivedi; Juha Hartikainen; Vesa Anttila; David Hildick-Smith; Leif Thuesen; Evald H Christiansen
Journal:  Lancet       Date:  2016-10-31       Impact factor: 79.321

Review 5.  Differences in interaction and subgroup-specific effects were observed between randomized and nonrandomized studies in three empirical examples.

Authors:  Amand F Schmidt; Maroeska M Rovers; Olaf H Klungel; Arno W Hoes; Mirjam J Knol; Mirjam Nielen; Antonius de Boer; Rolf H H Groenwold
Journal:  J Clin Epidemiol       Date:  2013-03-16       Impact factor: 6.437

6.  Randomized Trial of Stents Versus Bypass Surgery for Left Main Coronary Artery Disease: 5-Year Outcomes of the PRECOMBAT Study.

Authors:  Jung-Min Ahn; Jae-Hyung Roh; Young-Hak Kim; Duk-Woo Park; Sung-Cheol Yun; Pil Hyung Lee; Mineok Chang; Hyun Woo Park; Seung-Whan Lee; Cheol Whan Lee; Seong-Wook Park; Suk Jung Choo; CheolHyun Chung; JaeWon Lee; Do-Sun Lim; Seung-Woon Rha; Sang-Gon Lee; Hyeon-Cheol Gwon; Hyo-Soo Kim; In-Ho Chae; Yangsoo Jang; Myung-Ho Jeong; Seung-Jea Tahk; Ki Bae Seung; Seung-Jung Park
Journal:  J Am Coll Cardiol       Date:  2015-03-15       Impact factor: 24.094

7.  Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial.

Authors:  Daniel J F M Thuijs; A Pieter Kappetein; Patrick W Serruys; Friedrich-Wilhelm Mohr; Marie-Claude Morice; Michael J Mack; David R Holmes; Nick Curzen; Piroze Davierwala; Thilo Noack; Milan Milojevic; Keith D Dawkins; Bruno R da Costa; Peter Jüni; Stuart J Head
Journal:  Lancet       Date:  2019-09-02       Impact factor: 79.321

8.  Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study.

Authors:  Michael E Farkouh; Michael Domanski; George D Dangas; Lucas C Godoy; Michael J Mack; Flora S Siami; Taye H Hamza; Binita Shah; Giulio G Stefanini; Mandeep S Sidhu; Jean-François Tanguay; Krishnan Ramanathan; Samin K Sharma; John French; Whady Hueb; David J Cohen; Valentin Fuster
Journal:  J Am Coll Cardiol       Date:  2018-11-11       Impact factor: 24.094

9.  Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.

Authors:  Patrick W Serruys; Marie-Claude Morice; A Pieter Kappetein; Antonio Colombo; David R Holmes; Michael J Mack; Elisabeth Ståhle; Ted E Feldman; Marcel van den Brand; Eric J Bass; Nic Van Dyck; Katrin Leadley; Keith D Dawkins; Friedrich W Mohr
Journal:  N Engl J Med       Date:  2009-02-18       Impact factor: 91.245

10.  Strategies for multivessel revascularization in patients with diabetes.

Authors:  Michael E Farkouh; Michael Domanski; Lynn A Sleeper; Flora S Siami; George Dangas; Michael Mack; May Yang; David J Cohen; Yves Rosenberg; Scott D Solomon; Akshay S Desai; Bernard J Gersh; Elizabeth A Magnuson; Alexandra Lansky; Robin Boineau; Jesse Weinberger; Krishnan Ramanathan; J Eduardo Sousa; Jamie Rankin; Balram Bhargava; John Buse; Whady Hueb; Craig R Smith; Victoria Muratov; Sameer Bansilal; Spencer King; Michel Bertrand; Valentin Fuster
Journal:  N Engl J Med       Date:  2012-11-04       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.